$ News

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Unity reports topline outcomes from trial of diabetic macular oedema therapy

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

Unity Biotechnology initiated with bullish view at Rodman & Renshaw

UNITY Biotechnology to Participate in Upcoming Investor Conferences